Ocular Theraputics and Drug Delivery

Naslovnica
CRC Press, 12. pro 1995. - Broj stranica: 587
Since ocular therapeutics and drug delivery is a subject of interest to specialists from various disciplines such as chemical, biochemical, medical, pharmaceutical, and toxicological, it truly presents a unique situation requiring a multi-disciplinary approach in understanding and addressing various problems. Yet we see that scientists associated with these areas are working, by and large, independently of one another, thus limiting dissemination of knowledge, experience and ideas that would greatly enhance the overall progress in this area of research. Regrettably, the information currently available in ocular therapeutics and drug delivery, though extensive, is still fragmented into various disciplines making meaningful synthesis difficult. Several books are available that cover one or two aspects of the multi-disciplinary fields on an individual basis; however, none is available that covers all of them. The chapters contained in this book are specific to various interrelated areas of ocular therapeutics and drug delivery and are written by acknowledged experts from both academia and industry. The book itself is divided into five parts, namely: (I) overview,basic principles, and methodology; (II) pathopharmacology and clinical applications; (III) chemical/ biochemical approaches to ocular drug delivery; (IV) formulation and drug delivery considerations; and (V) industrial and regulatory considerations.
Individual chapters in each section, apart from presenting a concise text, entail an extensive listing of references.
 

Sadržaj

OCULAR THERAPEUTICS AND DRUG
3
Ocular Drug Disposition
9
Conventional Ophthalmic Dosage Forms
15
Ocular Toxicity
21
Wetting
33
OilWater Partitioning
39
BIOLOGICAL BARRIERS TO OCULAR DELIVERY
51
Structure and Function
75
Selected Case Studies of Prodrugs
296
Future PerspectivesConclusions
323
THE USE OF RETROMETABOLIC DRUG DESIGN
335
The Inactive Metabolite Approach in the Design
351
Conclusion
358
DEVELOPMENT OF SOFT DRUGS
363
Adaprolol Maleate
372
Adjuvants
379

Utility and Limitations
88
Conclusions
94
Appendix B
107
Appendix F
115
Appendix H
122
PHARMACOKINETIC AND PHARMACODYNAMIC
133
Ofloxacin
142
DRUG METABOLIZING ENZYME SYSTEMS
149
Enzymes
157
ARTIFICIAL TEAR FORMULATIONS IRRIGATING
171
Irrigating Solutions
185
Contact Lens Products
193
Conclusion
204
CLINICAL PHARMACOLOGY OF THE ANTERIOR
213
AntiInflammatory Agents
222
AntiInfective Agents
228
Conclusion
239
RECENT DEVELOPMENTS IN ANTIGLAUCOMA
245
PATHOLOGICAL
265
Viral Retinitis
272
CHEMICALBIOCHEMICAL APPROACHES TO OCULAR DRUG DELIVERY
283
Enzymes Responsible for Bioconversion
289
Sterility
391
Conclusion
398
POLYMERS IN OPHTHALMIC DRUG
405
Applications of Polymers in the Eye
417
Conclusions
430
MICROPARTICULATES AS AN OCULAR
441
Microparticulates as a Topical Ocular Delivery System
448
Multiparticulate Manufacture
455
PROTEIN AND PEPTIDE DRUG DELIVERY
461
Ocular Administration of PeptidesProteins
468
Specialized Delivery Systems
477
Anatomy of the Cornea and Its Relation to Ocular
499
Validation of in vitro Tests
505
Conclusion
512
PACKAGING ASPECTS OF OPHTHALMIC
529
A BRIEF HISTORY OF DRUG REGULATION
543
Regulatory IssuesRequirements
549
Bioregulations
557
Labeling Requirements
564
Acknowledgements
573
About the Editor 587
Autorska prava

Uobičajeni izrazi i fraze

Popularni odlomci

Stranica 583 - The rate and extent to which the active ingredient or active moiety is absorbed from a drug product and becomes available at the site of action.
Stranica 583 - ... intended to affect the structure or any function of the body of man or other animals, and which does not achieve any of its principal intended purposes through chemical action within or on the body of man or other animals and which is not dependent upon being metabolized for the achievement of any of its principal intended purposes.
Stranica 583 - ... extent of absorption of the listed drug when administered at the same molar dose of the therapeutic ingredient under similar experimental conditions in either a single dose or multiple doses and the difference from the listed drug in the rate of absorption of the drug is intentional, is reflected in its proposed labeling, is not essential to the attainment of effective body drug concentrations on chronic use, and is considered medically insignificant for the drug.
Stranica 583 - Pharmacopeia, or any supplement to them, (2) intended for use in the diagnosis of disease or other conditions, or in the cure, mitigation, treatment, or prevention of disease, in man or other animals...
Stranica 583 - ... Active ingredient means any com-ponent that is intended to furnish pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body of man or other animals. The term includes those com-ponents that may undergo chemical change in the manufacture of the drug product and be present in the drug product in a modified form intended to furnish the specified activity or effect. (8) Inactive...

Bibliografski podaci